Lantheus Expands Cancer Pipeline With $35M Acquisition of RM2 Rights
Lantheus Expands Cancer Pipeline With $35M Acquisition of RM2 Rights
Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acquisition of the global rights of Life Molecular Imaging's ("Life Molecular") RM2, targeting the gastrin-releasing peptide receptor (GRPR), including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair, referred to as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2. This acquisition strengthens Lantheus' presence in prostate cancer and expands its pipeline to include breast and other cancers. The agreement includes global rights1 to this radiotheranostic pair for an upfront payment of $35 million and potential regulatory milestone payments plus royalties.
Lantheus Holdings, Inc.("lantheus")(納斯達克:LNTH)是一家以放射性藥物爲中心的領先公司,致力於幫助臨床醫生找到、對抗和隨訪疾病,以提供更好的患者預後。今天宣佈收購全球權利生命分子成像("Life Molecular")的靶向胃泌素釋放肽受體(GRPR)的RM2,包括相關的新穎的、臨床階段的放射性治療和放射性診斷劑對,稱爲177Lu-DOTA-RM2和68Ga-DOTA-RM2。此次收購加強了Lantheus在前列腺癌領域的存在,並擴展了其實驗管道,包括乳腺癌和其他癌症。協議包括對這個放射治療對的全球權利1的前期款項爲3500萬美元和潛在的監管里程碑支付加版稅。
Lantheus' acquisition of worldwide rights to 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 underscores its dedication to pioneering cancer care and marks a significant step towards addressing unmet medical needs in prostate and breast cancer treatment. RM2 was discovered at the Universities Bern and Basel and development was originally performed by Bayer Pharma AG. It was subsequently licensed to Life Molecular. 68Ga-DOTA-RM2 targets cancers overexpressing GRPR, such as prostate, breast, lung, pancreatic, colorectal, gastric and ovarian cancers and has been extensively studied in various tumor types. First-in-human dosimetry showed a favorable safety and dosimetry profile and confirmed preclinical data demonstrating dose-dependent efficacy of 177Lu-DOTA-RM2. Lantheus intends to begin a Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer patients in 2025. 68Ga-DOTA-RM2 will be used as a companion diagnostic.
Lantheus's收購177Lu-DOTA-RM2和68Ga-DOTA-RM2的全球權利突出了其致力於開創癌症治療的精神,並標誌着在解決前列腺癌和乳腺癌治療中未滿足的醫療需求方面邁出了重要的一步。RM2是在伯爾尼大學和巴塞爾大學發現的,並最初由拜耳製藥公司開發。隨後被許可給了生命分子。68Ga-DOTA-RM2靶向GRPR過度表達的癌症,如前列腺、乳腺、肺、胰腺、結直腸、胃和卵巢癌,並在不同腫瘤類型中進行了廣泛的研究。首次使用人體劑量學研究顯示出有利的安全性和劑量學文件,並確認177Lu-DOTA-RM2劑量依賴性功效的臨床前數據。Lantheus計劃在2025年開始對前列腺癌患者進行177Lu-DOTA-RM2的第1/2a期研究。68Ga-DOTA-RM2將作爲伴侶診斷工具。